Open in PodwiseOpen

Podcast cover

BioSpace · Business

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Episodes

We Don't Own Patient Data–We're Just Babysitting It

Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings

Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions

Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines

AI Is Taking Over Drug Safety Monitoring–But There's One Thing It Can't Replace

FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease

Bonus Episode: Q2 2025 Job Market Update

The mRNA Revolution You Haven't Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

Understanding the FDA's AI Guidance in Pharmacovigilance

FDA Churn Continues, RFK Faces Congress, Obesity Insights at ADA, BIO2025 Recap

Navigating Funding Freezes and AI Frontiers

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

RFK Axes CDC Vaccine Advisors ; Metsera’s Weight Loss Win; FDA Supports CGT

AI's Role in Decoding the FDA's New Regulatory Communications

M&A Ticks Up, ASCO Excites and Vaccines Cause More Drama

COVID-19 Vaccine Overhaul, Rocket Grounded, ‘One Tough Hombre’ on MFN

How Target Product Profiles Guide the Industry Through Uncertain Times

Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan

Page 7

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise